{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Erythema+Multiforme",
    "query": {
      "condition": "Erythema Multiforme"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 24,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Erythema+Multiforme&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-04T05:43:28.336Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01638507",
      "title": "An Evaluation of the Commercially Available Medtronic Resolute Integrity Zotarolimus-Eluting Coronary Stent System",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Coronary Artery Disease"
      ],
      "interventions": [
        {
          "name": "Resolute Integrity Stent",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Medtronic Vascular",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 230,
      "start_date": "2012-07",
      "completion_date": "2015-06",
      "has_results": true,
      "last_update_posted_date": "2019-04-03",
      "last_synced_at": "2026-09-04T05:43:28.336Z",
      "location_count": 1,
      "location_summary": "Syracuse, New York",
      "locations": [
        {
          "city": "Syracuse",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01638507"
    },
    {
      "nct_id": "NCT02987257",
      "title": "NATIENS: Optimal Management and Mechanisms of SJS/TEN",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Stevens-Johnson Syndrome",
        "Toxic Epidermal Necrolyses"
      ],
      "interventions": [
        {
          "name": "Harmonized supportive care",
          "type": "DRUG"
        },
        {
          "name": "Etanercept 50 mg sc day 1 and day 4",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2023-03-21",
      "completion_date": "2025-10-31",
      "has_results": false,
      "last_update_posted_date": "2025-12-17",
      "last_synced_at": "2026-09-04T05:43:28.336Z",
      "location_count": 14,
      "location_summary": "Phoenix, Arizona • Sacramento, California • Washington D.C., District of Columbia + 11 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02987257"
    },
    {
      "nct_id": "NCT02126020",
      "title": "Topical Infliximab in Autoimmune Eyes With Keratoprosthesis",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Stevens-Johnson Syndrome",
        "Toxic Epidermal Necrolysis (Lyell) Syndrome",
        "Mucous Membrane Pemphigoid"
      ],
      "interventions": [
        {
          "name": "topical infliximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "James Chodosh, MD, MPH",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 0,
      "start_date": "2014-11",
      "completion_date": "2017-04-03",
      "has_results": false,
      "last_update_posted_date": "2017-04-07",
      "last_synced_at": "2026-09-04T05:43:28.336Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02126020"
    },
    {
      "nct_id": "NCT03044197",
      "title": "Detection of Clinically Significant Prostate Cancer Using Transperineal Targeted Biopsy Compared to Standard Transrectal Biopsy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Prostate Cancer",
        "Magnetic Resonance Imaging",
        "Target Lesion",
        "Fusion Biopsy",
        "Clinically Significant Prostate Cancer",
        "Transperineal"
      ],
      "interventions": [
        {
          "name": "MRI/ultrasound transperineal prostate biopsy",
          "type": "DEVICE"
        },
        {
          "name": "transrectal ultrasound-guided prostate biopsy",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "The University of Texas Medical Branch, Galveston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "MALE",
        "summary": "18 Years to 75 Years · Male only"
      },
      "enrollment_count": 24,
      "start_date": "2017-07-25",
      "completion_date": "2018-04-12",
      "has_results": true,
      "last_update_posted_date": "2019-06-05",
      "last_synced_at": "2026-09-04T05:43:28.336Z",
      "location_count": 1,
      "location_summary": "Galveston, Texas",
      "locations": [
        {
          "city": "Galveston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03044197"
    },
    {
      "nct_id": "NCT01913600",
      "title": "Resolute Integrity US Extended Length Sub-Study(RI US XL)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Coronary Artery Disease"
      ],
      "interventions": [
        {
          "name": "Resolute Integrity Stent",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Medtronic Vascular",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 56,
      "start_date": "2013-07",
      "completion_date": "2018-12",
      "has_results": true,
      "last_update_posted_date": "2019-05-08",
      "last_synced_at": "2026-09-04T05:43:28.336Z",
      "location_count": 1,
      "location_summary": "Syracuse, New York",
      "locations": [
        {
          "city": "Syracuse",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01913600"
    },
    {
      "nct_id": "NCT01479816",
      "title": "Urinary Continence Index for Prediction of Urinary Incontinence in Older Women",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Urinary Incontinence"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Ananias Diokno",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "55 Years and older · Female only"
      },
      "enrollment_count": 702,
      "start_date": "2011-09",
      "completion_date": "2015-12",
      "has_results": false,
      "last_update_posted_date": "2016-07-21",
      "last_synced_at": "2026-09-04T05:43:28.336Z",
      "location_count": 2,
      "location_summary": "Rochester, Michigan • Royal Oak, Michigan",
      "locations": [
        {
          "city": "Rochester",
          "state": "Michigan"
        },
        {
          "city": "Royal Oak",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01479816"
    },
    {
      "nct_id": "NCT04433572",
      "title": "Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Knee",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Peripheral Artery Disease",
        "Critical Limb Ischemia"
      ],
      "interventions": [
        {
          "name": "Temsirolimus",
          "type": "DRUG"
        },
        {
          "name": "Saline placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mercator MedSystems, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 250,
      "start_date": "2025-07-30",
      "completion_date": "2032-08-01",
      "has_results": false,
      "last_update_posted_date": "2025-08-05",
      "last_synced_at": "2026-09-04T05:43:28.336Z",
      "location_count": 2,
      "location_summary": "Houma, Louisiana • Dallas, Texas",
      "locations": [
        {
          "city": "Houma",
          "state": "Louisiana"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04433572"
    },
    {
      "nct_id": "NCT04203433",
      "title": "A Study of DLX105-DMP in Subjects With Plaque Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Plaque Psoriasis"
      ],
      "interventions": [
        {
          "name": "DLX105-DMP",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "DelArrivo, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 10,
      "start_date": "2022-03-21",
      "completion_date": "2022-09-01",
      "has_results": false,
      "last_update_posted_date": "2023-05-03",
      "last_synced_at": "2026-09-04T05:43:28.336Z",
      "location_count": 4,
      "location_summary": "Alpharetta, Georgia • Philadelphia, Pennsylvania • San Antonio, Texas + 1 more",
      "locations": [
        {
          "city": "Alpharetta",
          "state": "Georgia"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "Norfolk",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04203433"
    },
    {
      "nct_id": "NCT04313725",
      "title": "Evaluation of Tangible Boost for Patients With Stevens Johnson Syndrome, Sjogren's Syndrome, and Graft Vs Host Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Stevens-Johnson Syndrome",
        "Graft Versus Host Disease in Eye",
        "Sjogren's Syndrome",
        "Dry Eye"
      ],
      "interventions": [
        {
          "name": "Tangible Boost",
          "type": "DEVICE"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "Tangible Science",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2020-02-24",
      "completion_date": "2023-06-21",
      "has_results": false,
      "last_update_posted_date": "2025-09-16",
      "last_synced_at": "2026-09-04T05:43:28.336Z",
      "location_count": 1,
      "location_summary": "Needham, Massachusetts",
      "locations": [
        {
          "city": "Needham",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04313725"
    },
    {
      "nct_id": "NCT01893567",
      "title": "Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex® (Clobetasol Propionate) Spray 0.05%",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Plaque Psoriasis"
      ],
      "interventions": [
        {
          "name": "Clobex Spray",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Galderma R&D",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2013-07",
      "completion_date": "2013-10",
      "has_results": true,
      "last_update_posted_date": "2022-09-27",
      "last_synced_at": "2026-09-04T05:43:28.336Z",
      "location_count": 1,
      "location_summary": "Fort Gratiot, Michigan",
      "locations": [
        {
          "city": "Fort Gratiot",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01893567"
    }
  ]
}